HeartBeam Inc. (NASDAQ: BEAT) has made significant strides in cardiac care technology with its development of the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals in real time. This innovation allows patients to carry the HeartBeam System with them at all times, ready to record an ECG in just 30 seconds whenever symptoms arise, whether at home or elsewhere. The system's ability to reduce delays in care by enabling immediate symptom recording is a game-changer for patients and healthcare providers alike.
The HeartBeam System has already received FDA clearance for arrhythmia assessment, with its 12-lead ECG synthesis software currently under FDA review for the same indication. A recent partnership with AccurKardia further enhances HeartBeam's arrhythmia solution by incorporating an FDA-cleared automated rhythm interpretation software. With 20 issued patents and more pending, HeartBeam's proprietary technology is well-protected, covering its hardware, software, and algorithmic capabilities.
Targeting a $500 million concierge SAM and a broader multibillion-dollar patient pay market, HeartBeam is on the verge of commercial launch. Its high-margin, recurring revenue model supports the company's vision to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside traditional medical settings. This breakthrough not only promises to improve patient outcomes by facilitating timely care but also significantly reduces the need for wires, complex setups, or clinical staff, making synthesized 12-lead ECG signals accessible beyond the confines of a medical facility.
